arXiv:2606. 11794v1 Announce Type: cross Abstract: Neurodegenerative diseases such as Alzheimer's disease (AD) require accurate and scalable tools for assessing disease severity, yet current clinical staging remains time-intensive and prone to variability.
Summary generated by The Flow from the publisher's feed. The full article lives at arXiv AI.
In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits. Integrating these multimodal observations may improve diagnostic assessment, but naive fusion can degrade performance when MRI is noisy or intermittently unavailable.
arXiv:2607. 07091v1 Announce Type: cross Abstract: In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits.
arXiv:2606. 17867v1 Announce Type: cross Abstract: Despite increasing adoption of multimodal approaches in Alzheimer's Disease (AD) research -- aimed at integrating molecular, structural, clinical, and genetic biomarkers to enhance disease characterization -- the relationships among these modalities remain poorly understood.
arXiv:2607. 11656v1 Announce Type: cross Abstract: Accurate diagnostic classification and disease-severity prediction for Alzheimer's disease are hampered by the incompleteness and heterogeneity of real-world clinical data.
arXiv:2606. 20037v1 Announce Type: new Abstract: Alzheimer's disease (AD) is an irreversible neurodegenerative disorder and a leading cause of death worldwide.
arXiv:2606. 03995v1 Announce Type: cross Abstract: Background: Alzheimer's disease (AD) affects over 55 million people worldwide.